RxDoctor Payments DataLook up a doctor →

Sudhir Prasada, MD

Interventional Cardiology · Rocky Mount, NCNPI 1710971585

Payments from drug & device makers

$319,639in general payments, 2019–2025

Across 285 payments — averaging $1121.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$152K
  • AstraZeneca$55K
  • Astrazeneca UK Limited$40K
  • Boehringer Ingelheim$29K
  • Kowa Research Institute, Inc.$22K
  • Merck$15K
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$76616%
  • Food & beverage$4,07384%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$319,639 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$133,896
Medicare patients
871
Services billed
1,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$225,719
XareltoRivaroxaban63$53,247
BrilintaTicagrelor63$34,830
EntrestoSacubitril/Valsartan34$25,762
Repatha SureclickEvolocumab39$24,625
FarxigaDapagliflozin Propanediol28$23,969
NexletolBempedoic Acid41$19,081
MultaqDronedarone Hcl20$17,355
Ranolazine ErRanolazine167$11,333
JardianceEmpagliflozin12$10,951
Isosorbide Mononitrate ErIsosorbide Mononitrate490$5,403
Atorvastatin Calcium301$3,797
Metoprolol Succinate320$3,551
ClopidogrelClopidogrel Bisulfate298$2,828
Isosorbide Dinitrate21$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$222$225,719310 claims
AstraZenecaBrilinta, Farxiga$55,442$58,79991 claims
Johnson & JohnsonXarelto$146$53,24763 claims
NovartisEntresto$365$25,76234 claims
Esperion Therapeutics, Inc.Nexletol$22$19,08141 claims
Sanofi-aventis U.S. LLCMultaq$95$17,35520 claims
Boehringer IngelheimJardiance$29,339$10,95112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →